Illumina targets cancer diagnostics


Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system. The idea is to develop sequencing diagnostics to go alongside cancer therapies being developed by AstraZeneca, Janssen Biotech and Sanofi.

Because tumours’ susceptibility to certain drugs often depends on whether they carry mutations in one or more of around 125 cancer-related genes, identifying the right patients can make treating cancers more successful, and mean the difference between success and failure in clinical trials. As a result, more and more drugs are being approved only in conjunction with a companion diagnostic test.

But most of these tests so far rely on biomarkers, or partial gene sequencing. The price of sequencing is dropping rapidly, and Illumina intends to develop tests that involve sequencing panels of whole genes, rather than searching individually for specific variants. The firm is aiming to take advantage of the fact that it currently sells the only ‘next-generation’ sequencer that is approved for clinical use to establish a dominant position in a nascent sequencing market. 


Related Content

Illumina fends off Roche hostile bid

27 January 2012 News Archive

news image

Roche aims to expand personalised medicine diagnostics by acquiring the gene sequencing leader

Oligonucleotide drugs step up

23 September 2015 Premium contentFeature

news image

Structural innovations are overcoming oligonucleotide drugs’ historical flaws, discovers Andy Extance

Most Commented

Crawling chemical system acts as if it’s alive

24 May 2016 Research

news image

Intriguing globule that moves, eats and defecates

Let's see that again

27 May 2016 In the Pipeline

news image

Has chemistry evaded the reproducibility crises affecting other branches of science? Or is it just a question of scale, asks ...